Kintor Pharma completes patient enrollment in phase II trial of KX-826 in China to treat female patients with androgenetic alopecia

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (pyrilutamide) in China for the treatment of female androgenetic alopecia (AGA) on 4 March 2022, which has only taken around four months since its launch. The population of those who suffer from hair loss has a large number and tends to be younger, and hair loss is gradually becoming the focus of the whole society. By the end of 2020, the number of hair loss in China had exceeded 252 million. AGA, known as the most common type of hair loss, is a condition that can affect both men and women. In China, the prevalence of AGA is approximately 21.3% in males and 6.0% in females. Dr. Youzhi Tong, founder, chairman, and CEO of Kintor Pharma commented, "We are delighted to see the completion of the enrollment of all subjects in the phase II clinical trial of KX-826, and I would like to give special thanks to all the investigators, subjects and my team who participated in this clinical trial. In China, one in 20 female adults suffers from hair loss, and the ratio in male adults is 5:1. Hair loss has an important impact on patients' mental health and quality of life. We look forward to receiving preliminary data from this study in Q4 this year, further broadening the clinical potential of KX-826 in female AGA patients, and accelerating KX-826

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!